Cancer Genetics and Epigenetics 2024, Vol.12, No.4, 223-233 http://medscipublisher.com/index.php/cge 228 (VEGFR) have become standard treatments for metastatic RCC, demonstrating the impact of VHL mutations on personalized medicine (Kim et al., 2021). The application of VHL mutation status in tailoring targeted therapies and immunotherapies has shown promising results. The identification of VHL gene alterations allows for the selection of appropriate targeted therapies, such as VEGFR inhibitors, which have been effective in treating metastatic RCC (Kim et al., 2021). Additionally, the combination of anti-angiogenic agents with immune checkpoint inhibitors has emerged as a therapeutic strategy, leveraging the immunomodulatory effects of anti-VEGFR therapy (Figure 2) (Kim et al., 2021). These advances highlight the potential of using VHL mutation status to tailor treatment strategies, improving patient outcomes and advancing the field of personalized medicine in RCC. Figure 2 The VHL–HIF pathway and advances in treatments for metastatic ccRCC (Adopted from Kim et al., 2021) Image caption: : ccRCC, clear cell renal cell carcinoma; HIF, hopoxia-inducible factor; ICI, immune checkpoint inhibitor; mRCC, metastatic renal cell carcinoma; PD-1, programmed cell death protein 1; PD-1i, PD-1 inhibitor; PD-L1 programmed death-ligand 1; PD-L1i, PD-L1 inhibitor; TKI, tyrosine kinase inhibitor; TME, tumor microenvironment; VEGF, vascular endothelial growth factor; VEGFi, VEGF inhibitor; VEGFR, vascular endothelial growth factor receptor; VHL, von Hippel Lindau (Adopted from Kim et al., 2021) In conclusion, the VHL gene holds significant promise in the diagnosis, prognosis, and personalized treatment of kidney cancer. Its role as a biomarker for early detection, prognostic value in predicting patient outcomes, and application in guiding personalized treatment strategies underscore its importance in the clinical management of renal cell carcinoma. 5 Challenges in Utilizing VHLGene in Diagnosis 5.1 Technical and methodological limitations The detection of VHL gene alterations in renal cell carcinoma (RCC) presents several technical challenges. One significant issue is the sensitivity and specificity of the methods used to detect these alterations. Techniques such as multiplex ligation-dependent probe amplification (MLPA) and next-generation sequencing (NGS) have been employed to identify VHL mutations, loss of heterozygosity, and promoter hypermethylation. However, these methods can vary in their ability to detect all types of genetic alterations accurately. For instance, MLPA can identify intragenic copy number changes that might be missed by other methods, but it may not detect all point mutations or small indels effectively Banks et al., 2006). Additionally, the specificity of these tests can be compromised by the presence of non-tumor cells in the sample, leading to false-negative results. The variability in results depending on the method used is another significant challenge. Different techniques can yield different results for the same sample, complicating the interpretation of VHL status. For example, while
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==